ICOP-Pharm: could the new paradigm bridge a gap in evidence raised by 2022 ESC guidelines on cardio-oncology?-Reference-Cited by-同舟云学术

ICOP-Pharm: could the new paradigm bridge a gap in evidence raised by 2022 ESC guidelines on cardio-oncology?

Published:2022-12-02 Issue:11 Volume:44 Page:912-915
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Yaseen Israa Fadhil¹²^ORCID,Farhan Hasan Ali¹²^ORCID

Affiliation:

1. Baghdad Heart Center , Medical City, Bab Al-Muadham Street, Baghdad , Iraq

2. Scientific Council of Cardiology, Iraqi Board for Medical Specializations , Bab Al-Muadham Street, Baghdad , Iraq

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

https://academic.oup.com/eurheartj/article-pdf/44/11/912/49519968/ehac701.pdf

Reference9 articles.

1. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS);Lyon;Eur Heart J,2022

2. Effectiveness of pharmacist’s intervention in the management of cardiovascular diseases;Omboni;Open Heart,2018

3. Validity of medical history taken by pharmacists using a medical history taking tool;Matsushita;J Gen Fam Med,2017

4. Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study;Kappel;Curr Oncol,2019

5. Activity and outcomes of a cardio-oncology service in the United Kingdom—a five-year experience;Pareek;Eur J Heart Fail,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacists in oncology: Evidence still needed, but teaching comes first;Currents in Pharmacy Teaching and Learning;2024-08